| |
| |
 |
| |
|
|
| |
Plexxikon is pursuing a number of drug targets for the treatment of metabolic disease, with lead programs for type 2 diabetes and obesity indications.
PLX-204, the company's most advanced candidate for type 2 diabetes,
has advanced to Phase 2 clinical trials.
PLX-204 is a PPAR pan-agonist, targeting all three PPAR receptors, alpha, gamma and delta. In contrast to currently marketed PPAR compounds,
PLX-204's activity on all three receptors is expected to modulate lipids and cholesterol, as well as lower glucose. The multi-targeted compound, designed to be less potent on each individual receptor and a partial agonist, should have broader therapeutic activity and a wider safety window than current therapies.
Since October 2004, Plexxikon has been co-developing
a number of PPAR compounds with Wyeth, with a current
focus on candidates for the treatment of obesity.
Recently, Wyeth has decided to discontinue development
of PLX-204, and any PPAR compound for diabetes.
Under the collaboration agreement signed in 2004, Wyeth
and Plexxikon are continuing to develop two PPAR
compounds with distinct profiles for obesity.
Plexxikon is able to design PPAR compounds with activity against any of the three PPAR receptors or any combination of receptors, as well as vary the degree of agonism. Given this capability, the company is independently pursuing PPAR compounds with distinct profiles for the treatment of multiple sclerosis and inflammatory bowel disease.
 Metabolic Disease: Type 2 Diabetes Program Fact Sheet |
|
| |
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|
